Protection of DDAH2 overexpression against homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells.
Level 5 - mechanism / opinion, no new human data
In vitro bench research with no human clinical data
PubMed 23171931 · doi:10.1159/000343329
What was done
Liposome-mediated transfection was used to establish endothelial cells overexpressing dimethylarginine dimethylaminohydrolase 2 (DDAH2). Following treatment of cells with 1 mmol/L homocysteine for 24 hours, researchers evaluated the transcription and expression of DDAH1 and DDAH2, enzymatic activities of DDAH and nitric oxide synthase (NOS), and concentrations of asymmetric dimethylarginine (ADMA) and nitric oxide (NO).
What was found
No quantitative measurements, variance estimates, or exact p-values were reported in the abstract. Qualitatively, homocysteine significantly suppressed the transcription and expression of DDAH2 (but not DDAH1), decreased DDAH activity, elevated ADMA accumulation, inhibited NOS activity, and decreased NO production. DDAH2 overexpression prevented the decline of DDAH activity, decreased endogenous ADMA accumulation, and attenuated the reductions in NOS activity and NO production.
Why it matters
The findings identify DDAH2 downregulation as a mediator of homocysteine-induced endothelial dysfunction, pointing to DDAH2 expression as a potential therapeutic target in hyperhomocysteinemia-related vascular disease.
Limits
This is an in vitro cell culture study, which cannot capture complex in vivo cardiovascular physiology. The abstract provides no specific numerical values, effect sizes, or replicate numbers (n), and used a single high dose of homocysteine (1 mmol/L).
Cited by
- supports Elevated homocysteine impairs the clearance of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA).